Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumera I Ilyas

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Hepatology (Baltimore, Md.)|September 29, 2025
Multiomics combined with machine learning defines unique molecular subtypes of cholangiocarcinoma and identifies TNK1 as a therapeutic targetDong-Gi Mun, Erik Jessen, Jennifer L Tomlinson, et al.
Signal Transduction and Targeted Therapy|April 28, 2026
MARCO promotes cholangiocarcinogenesis by inducing immunosuppression and its targeting reduces tumor growthAloña Agirre-Lizaso, Maider Huici-Izagirre, Colm J O'Rourke, et al.
Journal of Hepatology|March 1, 2024
PTEN deficiency induces an extrahepatic cholangitis-cholangiocarcinoma continuum via aurora kinase A in miceYan Yang, Jiale Wang, Jianhua Wan, et al.
Journal of Hepatology|May 5, 2025
New platinum derivatives selectively cause double-strand DNA breaks and death in naïve and cisplatin-resistant cholangiocarcinomasIrene Olaizola, Mikel Odriozola-Gimeno, Paula Olaizola, et al.
Signal Transduction and Targeted Therapy|August 17, 2025
NADPH oxidase 1/4 dual inhibition impairs transforming growth factor-beta protumorigenic effects in cholangiocarcinoma cancer-associated fibroblastsJosep Amengual, Ester Gonzalez-Sanchez, Mariana Yáñez-Bartolome, et al.
Nature Reviews. Gastroenterology & Hepatology|July 2, 2020
Cholangiocarcinoma 2020: the next horizon in mechanisms and managementJesus M Banales, Jose J G Marin, Angela Lamarca, et al.
JHEP Reports : Innovation in Hepatology|March 10, 2025
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumabSimon Johannes Gairing, Philipp Mildenberger, Jennifer Gile, et al.
Hepatology (Baltimore, Md.)|February 2, 2026
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analysesYounghun Han, Jinyoung Byun, Caitlin J VanLith, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Hepatology (Baltimore, Md.)|September 29, 2025
Multiomics combined with machine learning defines unique molecular subtypes of cholangiocarcinoma and identifies TNK1 as a therapeutic targetDong-Gi Mun, Erik Jessen, Jennifer L Tomlinson, et al.
Signal Transduction and Targeted Therapy|April 28, 2026
MARCO promotes cholangiocarcinogenesis by inducing immunosuppression and its targeting reduces tumor growthAloña Agirre-Lizaso, Maider Huici-Izagirre, Colm J O'Rourke, et al.
Journal of Hepatology|March 1, 2024
PTEN deficiency induces an extrahepatic cholangitis-cholangiocarcinoma continuum via aurora kinase A in miceYan Yang, Jiale Wang, Jianhua Wan, et al.
Journal of Hepatology|May 5, 2025
New platinum derivatives selectively cause double-strand DNA breaks and death in naïve and cisplatin-resistant cholangiocarcinomasIrene Olaizola, Mikel Odriozola-Gimeno, Paula Olaizola, et al.
Signal Transduction and Targeted Therapy|August 17, 2025
NADPH oxidase 1/4 dual inhibition impairs transforming growth factor-beta protumorigenic effects in cholangiocarcinoma cancer-associated fibroblastsJosep Amengual, Ester Gonzalez-Sanchez, Mariana Yáñez-Bartolome, et al.
Nature Reviews. Gastroenterology & Hepatology|July 2, 2020
Cholangiocarcinoma 2020: the next horizon in mechanisms and managementJesus M Banales, Jose J G Marin, Angela Lamarca, et al.
JHEP Reports : Innovation in Hepatology|March 10, 2025
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumabSimon Johannes Gairing, Philipp Mildenberger, Jennifer Gile, et al.
Hepatology (Baltimore, Md.)|February 2, 2026
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analysesYounghun Han, Jinyoung Byun, Caitlin J VanLith, et al.
Pageof 6